Three‐monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid‐induced osteoporosis

Objective. Corticosteroids are widely prescribed, although treatment‐related side‐effects are common. Of these adverse events (AEs), osteoporosis is considered the most serious. Currently, oral bisphosphonates are the standard treatment for corticosteroid‐induced osteoporosis (CIO). However, intermi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of rheumatology 2003-06, Vol.42 (6), p.743-749
Hauptverfasser:	Ringe, J. D., Dorst, A., Faber, H., Ibach, K., Preuss, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alfacalcidol Back Pain - drug therapy Biological and medical sciences Bisphosphonate Bone density Bone Density - drug effects Calcaneus - physiopathology Corticosteroid‐induced osteoporosis Diphosphonates - administration & dosage Diphosphonates - therapeutic use Drug Administration Schedule Drug toxicity and drugs side effects treatment Female Femur Neck - physiopathology Fracture reduction Glucocorticoids - adverse effects Humans Hydroxycholecalciferols - therapeutic use Ibandronate Injections, Intravenous Lumbar Vertebrae - physiopathology Male Medical sciences Middle Aged Osteoporosis - chemically induced Osteoporosis - drug therapy Osteoporosis - physiopathology Pharmacology. Drug treatments Prospective Studies Spinal Fractures - prevention & control Toxicity: osteoarticular system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!